Trial Profile
An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms ODIN-BM
- Sponsors AstraZeneca
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 13 Jan 2021 Status changed from active, no longer recruiting to completed.
- 12 Jan 2021 According to Astra zeneca media release, data from this trial will be published at 2020 World Conference on Lung Cancer virtual conference to be held January 28-31, 2021.